

Nu Skin Enterprises Reports Third Quarter 2021 Results

November 3, 2021

PROVO, Utah, Nov. 3, 2021 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced third quarter 2021 revenue of \$641.2 million and earnings per share (EPS) of \$0.97.



Executive Summary Q3 2021 vs. Prior-year Quarter

	\$641.2 million; (9)%
Revenue:	+2% fx impact or \$11.8 million
Earnings Per Share (EPS):	\$0.97; (10)%
Sales Leaders:	58,565; (15)%
Customers:	1,395,271; (9)%

"As we previously announced, our third quarter revenue was lower than anticipated due to COVID delta variant disruptions as unexpected government restrictions interrupted selling and promotional activities in several markets, specifically in Mainland China and Southeast Asia," said Ryan Napierski, Nu Skin president and CEO. "Despite these short-term impacts, we are encouraged by our continued growth in the U.S., which was driven by our Beauty Focus Collagen+ launch and double-digit growth in Korea due to successful product promotions and sales leader initiatives.

"Looking ahead, we anticipate the ongoing rollout of our Collagen+ and ageLOC Meta products in Q4 will build momentum going into next year. For 2022 and beyond, we remain focused on our vision of becoming the world's leading beauty and wellness company, powered by our dynamic affiliate opportunity platform. We will work toward this by introducing our EmpowerMe personalized beauty and wellness strategy with connected beauty devices, increasing adoption of our affiliate-powered social commerce business model and expanding our digital platform. Amidst global uncertainty, we are confident in this strategy as we transform our company toward our vision for the future."

Q3 2021 Year-over-year Operating Results

	\$641.2 million compared to \$703.3 million
Revenue:	· +2% fx impact
	75.2% compared to 73.9%
Gross Margin:	Nu Skin business was 78.6% compared to 76.3%
	39.9% compared to 39.9%
Selling Expenses:	 Nu Skin business was 42.7% compared to 42.4%
G&A Expenses:	25.1% compared to 23.5%
Operating Margin:	10.2% compared to 10.6%
Other Income / (Expense):	\$2.8 million compared to \$0.5 million
Income Tax Rate:	27.0% compared to 24.7%
EPS:	\$0.97 compared to \$1.08

Dividend Payments:	\$19.0 million
	\$10.0 million
Stock Repurchases:	\$255.4 million remaining in authorization

Q4 and Full-year 2021 Outlook

	\$645 to \$675 million; (10) to (14)%
Q4 2021 Revenue:	Approximately (1)% fx impact
	\$0.90 to \$1.00; (29) to (36)%
Q4 2021 EPS:	 Prior year benefitted by 19.6% tax rate
	\$2.67 to \$2.70 billion; +3 to 5%
2021 Revenue:	Approximately +2 to 3% fx impact
2021 EPS:	\$3.93 to \$4.03; +8 to 11%

Mark Lawrence, chief financial officer, added, "We are adjusting our 2021 forecast based on third quarter results and continued COVID uncertainty. Despite the difficult operating environment, we anticipate annual revenue growth of 3 to 5 percent on top of strong growth in 2020, with earnings per share growth of 8 to 11 percent."

About Nu Skin Enterprises, Inc.

Nu Skin Enterprises, Inc. (NYSE: NUS) is a leading beauty and wellness company, powered by a dynamic affiliate opportunity platform. The company helps people live, look and feel their best with products that combine the best of science, technology and nature. Backed by more than 35 years of scientific research, Nu Skin develops innovative products including Nu Skin® personal care, Pharmanex® nutrition and the ageLOC® anti-aging brand which includes an award-winning line of beauty device systems. Nu Skin operates in approximately 50 markets worldwide in the Americas, Asia, Europe, Africa and the Pacific. Rhyz Inc. is the company's strategic investment arm that includes a collection of technology and manufacturing companies to support growth in the core Nu Skin business. Nu Skin is committed to sustainability, including global initiatives such as transitioning to reduced and sustainable packaging for all products by 2030. The Nu Skin Force for Good Foundation also strives to improve children's health, education and economic circumstances throughout the world. For more information, visit nuskin.com.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth, shareholder value, vision, initiatives, product pipeline and product introductions, digital tools, customers and sales leaders, affiliates, strategies and initiatives; projections regarding revenue, earnings per share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "anticipate," "project," "outlook," "guidance," "remain," "become," "plan," "forecast," "expand," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

- risk that epidemics, including the ongoing COVID-19 pandemic, and other crises could negatively impact our business;
- adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
- risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
- any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
- political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;
- uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
- risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations:
- uncertainties regarding the future financial performance of the businesses the company has acquired;
- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
- unpredictable economic conditions and events globally, including trade policies and tariffs;
- the company's future tax-planning initiatives; any prospective or retrospective increases in duties on the company's
 products imported into the company's markets outside of the United States; and any adverse results of tax audits or
 unfavorable changes to tax laws in the company's various markets; and

• continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.

The following table sets forth revenue for the three-month periods ended September 30, 2021 and 2020 for each of our reportable segments (U.S. dollars in thousands):

	Three Months Ended September 30,						Constant- Currency
		2021		2020		Change	Change
Nu Skin							
Mainland China	\$	134,291	9	5	169,068	(21)%	(26)%
Americas		131,482			133,618	(2)%	(2)%
South Korea		91,989			83,460	10%	8%
Southeast Asia/Pacific		79,081			101,949	(22)%	(23)%
EMEA		55,839			61,411	(9)%	(11)%
Japan		65,117			70,958	(8)%	(5)%
Hong Kong/Taiwan		39,921			42,265	(6)%	(8)%
Nu Skin other		889			(314)	383%	382%
Total Nu Skin		598,609			662,415	(10)%	(11)%
Rhyz Investments							
Manufacturing		41,635			40,910	2%	2%
Grow Tech		783			22	3,459%	3,459%
Rhyz other		125					
Total Rhyz Investments		42,543			40,932	4%	4%
Total	\$	641,152	\$	}	703,347	(9)%	(11)%

The following table sets forth revenue for the nine-month periods ended September 30, 2021 and 2020 for each of our reportable segments (U.S. dollars in thousands):

	Nine Months Ended September 30,				Constant- Currency	
		2021		2020	Change	Change
Nu Skin						
Mainland China	\$	438,066	\$	453,096	(3)%	(11)%
Americas		403,755		312,436	29%	28%
South Korea		261,724		236,094	11%	5%
Southeast Asia/Pacific		246,338		262,038	(6)%	(9)%
EMEA		215,134		147,590	46%	36%
Japan		203,001		200,549	1%	2%
Hong Kong/Taiwan		114,795		115,253		(4)%
Nu Skin other		2,350		374	528%	530%
Total Nu Skin		1,885,163		1,727,430	9%	5%
Rhyz Investments						
Manufacturing		135,760		105,975	28%	28%
Grow Tech		1,147		336	241%	241%
Rhyz other		163				
Total Rhyz Investments		137,070		106,311	29%	29%
Total	\$	2,022,233	\$	1,833,741	10%	6%

The company's Customers and Sales Leaders statistics by segment as of September 30, 2021 and 2020 are presented in the following table:

	= =:	s of er 30, 2021	As of September 30, 2020			crease crease)
	Customers	Sales Leaders	Customers Sales Leaders		Customers	Sales Leaders
Mainland China	355,256	13,838	341,386	20,970	4%	(34)%
Americas	324,880	12,127	397,936	12,798	(18)%	(5)%
South Korea	156,439	9,448	164,256	7,973	(5)%	18%
Southeast Asia/Pacific	162,048	7,607	204,489	9,959	(21)%	(24)%
EMEA	210,705	5,726	235,202	6,226	(10)%	(8)%
Japan	123,453	6,029	126,896	6,523	(3)%	(8)%
Hong Kong/Taiwan	62,490	3,790	69,346	4,067	(10)%	(7)%

$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Total	1,395,271	58,565	1,539,511	68,516	(9)%	(15)%
--	-------	-----------	--------	-----------	--------	------	-------

[&]quot;Customers" are persons who purchased products directly from the company during the previous three months. Our Customer numbers do not include consumers who purchase products directly from members of our sales force.

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Income (Unaudited)

(U.S. dollars in thousands, except per share amounts)

	Three Mor					nths Ended nber 30,	
	2021		2020		2021		2020
Revenue Cost of sales	\$ 641,152 158,907	\$	703,347 183,374	\$	2,022,233 501,448	\$	1,833,741 463,277
Gross profit	 482,245		519,973		1,520,785		1,370,464
Operating expenses: Selling expenses General and administrative expenses Total operating expenses	 255,719 161,142 416,861		280,695 165,050 445,745		807,358 499,754 1,307,112	_	735,365 466,232 1,201,597
Operating income Other income (expense), net	 65,384 2,781		74,228 525		213,673 351		168,867 (4,068)
Income before provision for income taxes Provision for income taxes	 68,165 18,436		74,753 18,446		214,024 57,527		164,799 46,911
Net income	\$ 49,729	\$	56,307	\$	156,497	\$	117,888
Net income per share: Basic Diluted	\$ 0.99 0.97	\$ \$	1.10 1.08	\$ \$	3.11 3.03	\$ \$	2.24 2.23
Weighted-average common shares outstanding (000s): Basic Diluted	50,098 51,260		51,308 52,243		50,304 51,629		52,741 52,906

NU SKIN ENTERPRISES, INC.

Consolidated Balance Sheets (Unaudited)

(U.S. dollars in thousands)

	Sep	tember 30, 2021	December 31, 2020		
ASSETS					
Current assets:					
Cash and cash equivalents	\$	282,412	\$	402,683	
Current investments		19,190		21,216	
Accounts receivable, net		52,441		63,370	
Inventories, net		415,203		314,366	
Prepaid expenses and other		121,626		101,563	
Total current assets		890,872		903,198	
Property and equipment, net		464,049		468,181	
Operating lease right-of-use assets		128,887		155,104	
Goodwill		215,582		202,979	
Other intangible assets, net		88,497		89,532	
Other assets		186,522		138,082	
Total assets	\$	1,974,409	\$	1,957,076	

[&]quot;Sales Leaders" are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.

Current liabilities:		
Accounts payable	\$ 52,023	\$ 66,174
Accrued expenses	378,573	446,682
Current portion of long-term debt	110,000	30,000
Total current liabilities	540,596	542,856
Operating lease liabilities	95,741	112,275
Long-term debt	278,563	305,393
Other liabilities	123,032	102,281
Total liabilities	1,037,932	1,062,805
Commitments and contingencies		
Stockholders' equity:		
Class A common stock – 500 million shares authorized, \$0.001 par value, 90.6 million shares		
issued	91	91
Additional paid-in capital	590,678	579,801
Treasury stock, at cost – 40.5 million and 39.7 million shares	(1,518,535)	(1,461,593)
Accumulated other comprehensive loss	(75,658)	(64,768)
Retained earnings	 1,939,901	 1,840,740
Total stockholders' equity	 936,477	894,271
Total liabilities and stockholders' equity	\$ 1,974,409	\$ 1,957,076

C View original content to download multimedia: https://www.prnewswire.com/news-releases/nu-skin-enterprises-reports-third-quarter-2021-results-301415504.html

SOURCE Nu Skin Enterprises

Media: media@nuskin.com, (801) 345-6397, or Investors: investorrelations@nuskin.com, (801) 345-3577